Steven H Liang

This patent presents novel substituted tetrahydrocyclohepteneindole derivatives as selective estrogen receptor alpha (ERα) inhibitors. These compounds demonstrate potential for treating Erα-related diseases such as cancers, ovulatory dysfun…